, Japan
-
Journal of Regulatory Science Vol. 8 (2020) - Review Articles
Japanese Pharmaceutical Industry: Recent Perspectives and Areas for Further Research
Abstract PDF -
Journal of Regulatory Science Vol. 4 No. 3 (2016) - Scientific Articles
Emerging Growth of Orphan Drugs for Neurological Diseases in Japan: Potential Benefits for Both Patients and Pharmaceutical Companies
Abstract PDF Figure 1 Figure 2 Figure 3 -
Journal of Regulatory Science Vol. 8 (2020) - Scientific Articles
Potential Impact of Accelerated Approval on the Drug Lags for Anticancer Drugs Between the United States and Japan
Abstract PDF -
Journal of Regulatory Science Vol. 4 No. 4 (2016) - Scientific Articles
Comparison of Regulations for the Development of Oncolytic Virus Therapy in the United States, the European Union, and Japan.
Abstract PDF -
Journal of Regulatory Science Vol 7 (2019) - Scientific Articles
Can Rare Cancer Drugs Expect Sales in Japan?: A Prescription Pattern Analysis of Drugs for Chronic Myelogenous Leukemia and Neuroendocrine Tumor
Abstract PDF -
Journal of Regulatory Science Vol. 5 No. 1 (2017) - Scientific Articles
Effective Use of Foreign Clinical Data in Approvals for Medical Devices in Japan
Abstract PDF -
Journal of Regulatory Science Vol 5, No 2 (2017) - Review Articles
Selective Safety Data Collection in Clinical Studies of Oncology Drugs for Marketing Approval in the United States
Abstract PDF -
Journal of Regulatory Science Vol. 4 No. 1 (2016) - Scientific Articles
A Comprehensive Analysis of Factors That Contribute to Conditional Approval and All-Case Surveillance Designations That Subsequently Lead to Shortening of Review Times in Japan
Abstract PDF Figures 1-4 (PDF file) -
Journal of Regulatory Science Vol 6, No 2 (2018) - Scientific Articles
Is the total review time of new medical devices related to the size of the company?: Medical devices development and its related factors in Japan
Abstract PDF